论文部分内容阅读
目的:评估甘精胰岛素用于治疗糖尿病的降糖作用和安全性。方法:按门诊就诊顺序连续选择血糖控制欠佳的糖尿病患者20例,其中1型糖尿病8例,2型糖尿病12例。在原治疗方案基础上加用或将中效胰岛素换为甘精胰岛素,疗程16周,观察治疗后空腹血糖(fasting blood glucose,FBG)、糖化血红蛋白A1C(glycosylated hemoglobin A1c,GHbA1C)、体重变化及低血糖的情况。结果:试验前FBG、GHbA1C分别是(7·5±1·6)mmol/L、0·074±0·014,终点时FBG、GHbA1C分别是(5·7±0·6)mmol/L、0·061±0·006,前后比较差异有统计学意义(分别为P<0·05,P<0·01);试验前体重指数为(23·0±1·8)kg/m2,终点时为(23·3±1·7)kg/m2,两者比较差异无统计学意义(P>0·5);治疗过程中低血糖发生少,仅1例次。结论:甘精胰岛素可以使糖尿病患者的FBG、GHbA1C均达到理想控制目标,而且不会增加体重,低血糖发生率低,使用方便。
Objective: To evaluate the hypoglycemic effect and safety of insulin glargine for the treatment of diabetes. Methods: According to outpatient treatment sequence of 20 consecutive patients with poor glycemic control were selected, including type 1 diabetes in 8 cases and type 2 diabetes in 12 cases. On the basis of the original treatment plan, the medium-acting insulin was replaced by insulin glargine for 16 weeks. The fasting blood glucose (FBG), glycosylated hemoglobin A1c (GHbA1C), weight change and low Blood sugar situation. Results: Before the experiment, FBG and GHbA1C were (7.5 ± 6.1) mmol / L and 0 · 074 ± 0 · 014, respectively. The mean FBG and GHbA1C at the end of the experiment were (5 · 7 ± 0.6) mmol / L, 0 · 061 ± 0 · 006, the difference was statistically significant before and after (P <0.05, P <0.01); before the test, the body mass index was (23.0 ± 1.8) kg / m2, (23.3 ± 1.7) kg / m2, there was no significant difference between the two groups (P> 0.05). The incidence of hypoglycemia in treatment was less than 1 case. Conclusion: Glargine can make FBG and GHbA1C of diabetic patients achieve the goal of ideal control without increasing body weight, low incidence of hypoglycemia and easy to use.